Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

The advent of PSMA-PET has improved sensitivity and specificity in staging prostate cancer, particularly in intermediate- and high-risk disease. This has created uncertainty in the management of patients with PSMA-positive but conventionally negative pelvic lymphadenopathy (i.e., \<1 cm in smallest diameter). This study evaluates outcomes of enhanced androgen deprivation therapy (ADT) with abiraterone and prednisone compared to standard ADT, both in combination with radiation therapy, in patients with prostate cancer and PSMA-positive but conventionally negative pelvic lymphadenopathy. A tot

Trial Details

NCT ID
NCT07237269
Phase
PHASE2
Sponsor
University of Nebraska
Status
RECRUITING
Cancer Type
Hormone-Sensitive Prostate Cancer
Interventions
  • Androgen Deprivation Therapy (ADT)
  • Abiraterone
  • Prednisone
  • Radiation Therapy
Locations (sample)
  • Omaha, Nebraska, United States|41.25626,-95.94043

Key Eligibility Criteria

  • Histopathologically proven diagnosis of local prostate cancer. Biopsies will be confirmed by UNMC pathology review if collected outside our institu…
  • Targetable PSMA-avid pelvic lymph node measuring \<1cm in short axis diameter.
  • No prior definitive treatment or intervention received.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 within 14 days prior to registration.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Hormone-Sensitive Prostate Cancer Trials on Trialify →